Aptâmeros A6 e A11 com potencial aplicação teranóstica em câncer de próstata

• Autor(a) principal: Simião, Maria Paula Silva
• Data de Publicação: 2024
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório Institucional da UFU
• Texto Completo: https://repositorio.ufu.br/handle/123456789/41654
• topic: Câncer de próstata; Aptâmeros; Teranóstica; Prostate cancer; Aptamers; Theranostics; CNPQ::CIENCIAS BIOLOGICAS

Prostate cancer (PCa) is the second most common type of cancer in men. Metastatic PCa is considered a more advanced type of tumor with a worse prognosis, therefore, it is important to diagnose the disease at an early stage, as well as choose the best treatment option for the patient. Aptamers are oligonucleotides that allow the search for biomarkers in target cells and can also provide information related to diagnosis, therapy and disease mechanisms. The objective of the study was to evaluate, using the resazurin method, whether there was a change in cell proliferation and viability of prostate lines when incubated with aptamers A6 and A11. The highest concentration of aptamer A6 used showed cytotoxicity in the tumor lineage and was not cytotoxic to the normal prostate lineage. The A11 aptamer did not influence cell viability and proliferation characteristics in both prostate lineages. These data suggest that aptamer A6 can be used as a therapy in patients with PCa, while A11 can be used as a possible diagnostic tool. Other analyzes and tests are needed to validate this information.